GlaxoSmithKline (GSK) is making major changes to its incentive schemes following a damaging corruption scandal in China.
The pharmaceuticals company will stop paying doctors to promote its products through speaking engagements.
Members of its sales force will also no longer have individual sales targets.
Earlier this year, police in China said GSK had transferred 3 billion yuan ($US489 million) to travel agencies and consultancies to help bribe doctors.
"Today we are outlining a further set of measures to modernise our relationship with healthcare professionals,'' said GSK chief executive Sir Andrew Witty in a statement.
"These are designed to bring greater clarity and confidence that whenever we talk to a doctor, nurse or other prescriber, it is patients' interests that always come first."
As well as stopping payments to doctors for making speeches, GSK is also ending payments to those attending medical conferences.
A spokesperson told the BBC that there were "perceived conflicts of interest with that way of working".
The British Medical Association said it agreed that GSK should not directly sponsor doctors going to meetings.
